Intellia Therapeutics Inc NTLA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/24/24 EDT
24.75quote price arrow down-0.09 (-0.36%)
Volume
62,653
Close
24.84UNCH (UNCH)
Volume
770,257
52 week range
19.37 - 47.48
Loading...
  • Open25.11
  • Day High25.17
  • Day Low24.61
  • Prev Close24.88
  • 52 Week High47.48
  • 52 Week High Date06/14/23
  • 52 Week Low19.37
  • 52 Week Low Date04/26/24

Key Stats

  • Market Cap2.396B
  • Shares Out96.48M
  • 10 Day Average Volume1.33M
  • Dividend-
  • Dividend Yield-
  • Beta1.87
  • YTD % Change-18.53

KEY STATS

  • Open25.11
  • Day High25.17
  • Day Low24.61
  • Prev Close24.88
  • 52 Week High47.48
  • 52 Week High Date06/14/23
  • 52 Week Low19.37
  • 52 Week Low Date04/26/24
  • Market Cap2.396B
  • Shares Out96.48M
  • 10 Day Average Volume1.33M
  • Dividend-
  • Dividend Yield-
  • Beta1.87
  • YTD % Change-18.53

RATIOS/PROFITABILITY

  • EPS (TTM)-5.37
  • P/E (TTM)-4.63
  • Fwd P/E (NTM)-4.64
  • EBITDA (TTM)-507.898M
  • ROE (TTM)-43.60%
  • Revenue (TTM)52.604M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-922.94%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Intellia Therapeutics Inc

Profile

MORE
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet...
Frank Verwiel M.D.
Independent Chairman of the Board
John Leonard M.D.
President, Chief Executive Officer, Director
Glenn Goddard
Chief Financial Officer, Executive Vice President, Treasurer
Michael Dube
Chief Accounting Officer, Vice President
Derek Hicks
Executive Vice President, chief business officer
Address
40 Erie St Ste 130
Cambridge, MA
02139-4254
United States

Top Peers

SYMBOLLASTCHG%CHG
MRUS
Merus NV
59.99UNCHUNCH
CLDX
Celldex Therapeutics Inc
36.92UNCHUNCH
MLTX
MoonLake Immunotherapeutics
40.85UNCHUNCH
JANX
Janux Therapeutics Inc
45.37UNCHUNCH
RXRX
Recursion Pharmaceuticals Inc
9.16UNCHUNCH